

# Source details

## Journal of Infection in Developing Countries

Open Access ⓘ

Scopus coverage years: from 2007 to 2022

Publisher: Open Learning on Enteric Pathogens

ISSN: 1972-2680 E-ISSN: 2036-6590

Subject area: Medicine: Infectious Diseases Immunology and Microbiology: Parasitology  
Immunology and Microbiology: Microbiology Immunology and Microbiology: Virology

Source type: Journal

CiteScore 2021 ⓘ  
**2.4**

SJR 2021 ⓘ  
**0.471**

SNIP 2021 ⓘ  
**0.698**

[View all documents >](#) [Set document alert](#) [Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

**i** Improved CiteScore methodology ✕

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ⌵

$$2.4 = \frac{2,156 \text{ Citations 2018 - 2021}}{898 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$3.2 = \frac{3,036 \text{ Citations to date}}{955 \text{ Documents to date}}$$

Last updated on 05 January, 2023 • Updated monthly

### CiteScore rank 2021 ⓘ

| Category                    | Rank     | Percentile |
|-----------------------------|----------|------------|
| Medicine                    |          |            |
| ↳ Infectious Diseases       | #190/295 | 35th       |
| Immunology and Microbiology |          |            |
| ↳ Parasitology              | #46/68   | 33rd       |
| Immunology and Microbiology |          |            |
| ↳ Microbiology              | #127/156 | 18th       |

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &](#)



## Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Ar Available Online


Hindawi



## Journal of Infection in Developing Countries

### COUNTRY

Italy

 Universities and research institutions in Italy

### SUBJECT AREA AND CATEGORY

Immunology and Microbiology  
Microbiology  
Parasitology  
Virology

Medicine  
Infectious Diseases  
Medicine (miscellaneous)

### PUBLISHER

Journal of Infection in Developing Countries

### H-INDEX

**53**

Complexity OA & Peer Reviewed



Open

### PUBLICATION TYPE

Journals

### ISSN

19722680, 20366590

### COVERAGE

2007-2021

### INFORMATION

[Homepage](#)  
[How to publish in this journal](#)  
[waiverequest@jidc.org](mailto:waiverequest@jidc.org)

Complexity OA & Peer Reviewed



Open

### SCOPE

The Journal of Infection in Developing Countries (JIDC) is an international journal, intended for the publication of scientific articles from Developing Countries by scientists from Developing Countries. JIDC is an independent, on-line publication with an international editorial board. JIDC is open access with no cost to view or download articles and reasonable cost for publication of research articles, making JIDC easily available to scientists from resource restricted regions.



Join the conversation about this journal

### Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Ar Available Online

Hindawi

Quartiles

#### FIND SIMILAR JOURNALS


options

|  |   |  |  |  |
|--|---|--|--|--|
| <p>1</p> <p><b>Journal of Infection and Public Health</b><br/>NLD</p> <p><b>86%</b><br/>similarity</p> | <p>2</p> <p><b>Canadian Journal of Infectious Diseases and EGY</b></p> <p><b>85%</b><br/>similarity</p> | <p>3</p> <p><b>Brazilian Journal of Infectious Diseases</b><br/>BRA</p> <p><b>78%</b><br/>similarity</p> | <p>4</p> <p><b>Archives of Clinical Infectious Diseases</b><br/>IRN</p> <p><b>77%</b><br/>similarity</p> | <p>5</p> <p><b>International Journal of Infectious Diseases</b><br/>NLD</p> <p><b>76%</b><br/>similarity</p> |
|--|---|--|--|--|

### Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Ar Available Online

Hindawi



Journal of Infection in Developing Countries

← Show this widget in your own website

Q3 Infectious Diseases best quartile

SJR 2021 0.47

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com/journalsearch.php?q=17700155407&tip=...">
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool**.



## Vol. 16 No. 10: October 2022

PUBLISHED: 2022-10-31

### Coronavirus Pandemic

#### Factors predicting caregivers' readiness for vaccination of 5-11 years old children against SARS-CoV-2 - Saudi Arabia, 2022

Ameinah Thamer Al-Rasheedi, Mohammed Ahmed Elmuttalut, Raghad Hamad AL-Mithn, Ghaida Saleh AL-Harbi, Ghadah Saleh Al-Ghufaili, Yara Hamad Al-Mohimeed, Anhar Ali Al-Qutaymi, Sarah Abdulrahman Al-Arfaj

1533-1541

 PDF

#### Intravenous high dose vitamin C and selected antiviral drugs in hospitalized COVID-19 patients: a descriptive cohort study

Mohamad Fleifel, Jonathan Mina, Tony Haykal, Rana Asmar, Ghida El Hout, Ranime Harb, Hani Dimassi, Jacques Mokhbat, Anna Farra, Rola Husni-Samaha

1542-1554

 PDF

#### Prognostic predictors for mortality of patients with COVID-19 in an intensive care unit

Hulya Abali, Hatice Kutbay Ozcelik, Esra Akkutuk Ongel, Nazan Beyhan, Fatma Tokgoz Akyil, Seda Tural Onur, Sedat Altin

1555-1563

 PDF

#### Evaluation of inflammatory and hematological parameters in patients diagnosed with COVID-19

Çiğdem Mermutluoğlu, Recep Dursun, Fesih Aktar, Saim Dayan, Mustafa Kemal Çelen, Ali Kemal Kadiroğlu, Erdal İnci, Rengin Karagöz, Mahir Kuyumcu, Nida Özcan, Recep Tekin

1564-1569

**PDF**

### **Face mask use and disposal behaviour of frontline young doctors during the COVID-19 pandemic: a two-year study**

Shibaji Gupta, Arup Chakraborty, Rudradeep Banerjee, Abhishek De, Sohini Halder, Debasis Das  
1570-1577

**PDF**

### **Impact of prolonged wearing of face masks – medical and forensic implications**

Ankita Guleria, Kewal Krishan, Vishal Sharma, Tanuj Kanchan  
1578-1587

**PDF**

### **Knowledge, attitudes, and practices towards COVID-19 among residents of Quang Binh, Vietnam**

Thanh-Tung Ho, Galal A Al-Samhari, Jun-Jie Lin, Jing-Jing Luo, Yueming Jiang  
1588-1595

**PDF**

## **Original Articles**

### **Tetanus immunization among healthcare professionals: cross-sectional study in Turkey**

Merve Sefa Sayar, Mustafa Özgür Akca, Ali Asan, Ali Gümüş, Sibel Yorulmaz Göktaş, İsmail Necati Hakyemez, Özgür Dağlı, Çınar Öztürk  
1596-1601

**PDF**

### **Effect of the cavity disinfectant containing chitosan on dentin bonding strength after radiotherapy**

Derya Gursel Surmelioglu, Ayşenur Gungor Borsoken, Gorkem Kervancioglu, N Ezgi Yeniceri Hilaloglu  
1602-1606

**PDF**

### **Antibiotic use and resistance: Information sources and application by dentists in Jordan**

Ghaith M Al-Taani, Sayer Al-Azzam, Reema A Karasneh, Mera Ababneh, Ola B Al-Batayneh, Yousef S

Khader, Barbara R Conway, Mamoon A Aldeyab  
1607-1613



### **Burden of disease attributed to acute respiratory infections in South America**

Gabriela Bittencourt Gonzalez Mosegui, Fernando Antoñanzas Villar, Cid Manso de Mello Vianna  
1614-1622



### **Parents' knowledge, attitude and practice towards seasonal influenza vaccination in Riyadh region, Saudi Arabia**

Kamel A Alenazi  
1623-1629



### **Polymerase chain reaction of human cytomegalovirus from liver and urine compared with serological test in cholestasis infants**

Alphania Rahniayu, Gondo Mastutik, Anny Setijo Rahaju, Siti Eriaty Nur Ruslan, Priangga Adi Wiratama, Erna Sulistiyani, Bagus Setyoboedi  
1630-1636



### **Molecular typing of dengue virus in Mizoram, Northeast India**

Christine Vanlalbiakdiki Sailo, Souvik Ghatak, Subbarayan Sarathbabu, Girija Shankar Bariha, Ayan Majumder, Abhinav Singh, Ralte Lalremruata, Eric Zomawia, Benjamin Lalrinpuia, Lalfak zuali, John Zothanzama, Nachimuthu Senthil Kumar  
1637-1642



## **Brief Original Articles**

### **Pneumocystis jirovecii colonization in bronchoalveolar lavage among naïve non-small cell lung cancer from tertiary respiratory hospital in Jakarta, Indonesia**

Jamal Zaini, Abul A'la Al Maududi, Tasya Fillahihasanah, Muhamad Rizqy Fadhillah, Prasenohadi Pradono, Budi Haryanto, Robiatul Adawiyah, Findra Setianingrum, Anna Rozaliyani, Elisna Syahrudin  
1643-1647



## Letters to the Editor

### Global Health priorities: repositioning routine immunization for infants

Saverio Bellizzi, Giuseppe Pichierri, Khalid Kheirallah, Catello M Panu Napodano

1648-1649



## Case Reports

### A clinical case and a review of Mycobacterium fortuitum infections direct diagnosis approach and treatment in a patient with leg fractures

Jun Wang, Jing Huang, Shijie Peng, Lianbao Li, Kaijing Zhong, Taigui Chen

1650-1654



### A rare presentation of tubercular osteomyelitis of the foot

Marco Pes, Veronica Amorese, Andrea Baioni, Matthew Gavino Donadu, Paola Molicotti, Fabio Milia, Carlo Doria

1655-1659



### Acute hepatitis in a paediatric patient: immune-mediated drug-induced liver injury or albendazole-induced autoimmune hepatitis?

Nataša Dragutinović, Aleksandra Barać, Goran Stevanović, Irena Đorđić, Bianca Paglietti, Jelena Micić, Ema Aleksić, Jelena Stojnić, Jelena Martinov Nestorov

1660-1663



### Biliary fascioliasis – A rare differential diagnosis of biliary obstruction

Phuong Anh Ton Nu, Thi Minh Chau Ngo, Vinh Nguyen Phuoc, Thanh Dang Nhu, Anh Do Ngoc, Le Chi Cao

1664-1667



### Isolation of an obscure fungus, Parengyodontium album, from the blood of a severely neutropenic patient: The first reported case from Malaysia



## Editorial Team

\* Starred names are JIDC Founders

### Editor in Chief

**Salvatore Rubino \***, Department of Biomedical Sciences, University of Sassari, Sassari, Italy

### Senior Editors

**Mohammed N Al-Ahdal**, King Faisal Specialist Hospital and Research Center, Saudi Arabia

**Mark Cameron**, Vaccine & Gene Therapy Institute of Florida, United States

**Piero Cappuccinelli \***, DBC, Clinical Microbiology, Sassari University, Italy and Carlo Urbani Centre, HCMP, Hue University, Vietnam

**Salih Hosoglu**, Dicle University Hospital, Diyarbakir, Turkey

**David J. Kelvin \***, International Inst. of Infection and Immunity, Shantou University Medical College, Shantou, China

**Peter Mason † \***, Zimbabwe

**Fawza Monem**, Damascus University, Syrian Arab Republic

**Iruka N. Okeke**, Haverford College, United States

**Abiola C. Senok**, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, EAU

**Athanassios Tsakris**, Medical School, University of Athens, Greece

**John Wain \***, Norwich Medical School, University of East Anglia, Norwich, United Kingdom

**Aysegul Karahasan Yagci**, Marmara University, Department of Clinical Microbiology, Istanbul, Turkey



**Guan Yi**, State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong

## Editors

Vicente Sperb Antonello, Department of Prevention and Infection Control Hospital Fêmina, Porto Alegre, RS, Brazil

Maria D Appleman, Microbial Research Laboratory, Los Angeles County + University of Southern California Medical Center, Los Angeles, USA

Lela Bakanidze, NCDC Georgia, Georgia

Aleksandra Barac, Clinic for Infectious and tropical Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade

Marie Anne Chattaway, Gastrointestinal Bacteria Reference Unit (GBRU), Microbiology Services, Public Health England, London, United Kingdom

Phyllis Della-Latta, Columbia Univ Med Ctr, NewYork Presbyterian Hosp, United States

Rajni Gaiind, VMMC and Safdarjung Hospital, New Delhi.India, India

Javier Garaizar, Dept. Immunol., Microbiol, and Parasitol., Faculty of Pharmacy, University of the Basque Cuntry, Vitoria-Gasteiz, Spain

Jorg Heukelbach, Department of Community Health, Federal University of Ceará, Brazil, Brazil

Ana Herrero Fresno, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark

Mario Poljak, Laboratory for Molecular Microbiology and Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia

Alfonso J. Rodriguez-Morales, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia

Pablo Zunino, Instituto de Investigaciones Biológicas Clemente Estable (IIBCE), Montevideo, Uruguay

## Associate Editors

Sojan Abraham, Texas Tech University Health Sciences Center, El Paso, Texas, USA

Kabiru Olusegun Akinyemi, Department of Microbiology, Lagos State University, Ojo, Lagos , Nigeria

Alberto Alberti, Department of Veterinary Medicine, University of Sassari, Sassari, Italy

Myo Nyein Aung, WHO Collaborating Center for Medical Education, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Ammar Ayachi, Veterinary Microbiology and Immunology, Veterinary Department, Batna University, Algeria

Cheryl Cameron, Vaccine & Gene Therapy Institute of Florida, United States

Muge Cevik, University of St Andrews, St Andrews, Unuited Kingdom

Chao Chen, Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA

Camila Coelho, National Institute of Allergy and Infectious Diseases (NIAID) / NIH, Washington D.C., USA

Carlo Contini, Infectious Diseases Unit, Universisty of Ferrara, Italy

Pablo Diaz, Department of Animal Pathology, Faculty of Veterinary Sciences, University of Santiago de Compostela, Lugo, Spain

Miranda Drogari-Apiranthitou, Medical School, University of Athens, Greece

Vitor Duque, Serviço de Infecções. Hospitais da Universidade de Coimbra, EPE. Portugal

Amber Farooqui, International Inst.of Infection and Immunity, Shantou University Medical College, China

Adnan Khan, Karachi University, Pakistan

Alyson Ann Kelvin, Department of Pediatrics, IWK Health Centre and Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada

Kewal Krishan, Department of Anthropology, Panjab University, India

Carine Leite, Departamento de Gastroenterologia e Endoscopia, Hospital Moinhos de Vento, Porto

Alegre, RS, Brasil

Liping Li, Department of Statistics, Department of Computer Science, Rutgers University, Piscataway, NJ, USA

Daniel Limonta, University of Alberta, Department of Cell Biology, Edmonton, AB, Canada

Alberto Enrico Maraolo, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Aleksandar Masic, Vetrepharm Research Inc., London, Ontario, Canada

Chinyere Okoro, Department of Medicine, University of Cambridge Cambridge, United Kingdom

David SY Ong, .Department of Medical Microbiology, University Medical Center Utrecht (UMCU), The Netherlands

Marina Pekmezovic, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Dept. Microbial Pathogenicity Mechanisms, Jena, Germany

Edmond Puca, Department of Infectious Disease, UHC "Mother Teresa", Tirana, Albania

Thomas Rowe, Centers for Disease Control and Prevention, United States

Anthony Smith, Centre for Enteric Diseases, National Institute for Communicable Diseases, South Africa

William Snelling, School of Biomedical Sciences, University of Ulster, Coleraine, N. Ireland

Nijaz Tihic, University Clinical Center Tuzla, Department of Microbiology, Bosnia and Herzegovina

Danielle Tropsens, Journal of Infection in Developing Countries, Germany

Darinka Vuckovic, University of Rijeka, Rijeka, Croatia

Lifei Yang, Scripps Research Institute, San Diego, CA, United States

Dominik Zenner, Centre for Infectious Disease Surveillance and Control Public Health England, London UK, United Kingdom

Roberto Zenteno, Instituto de Salud Publica, Universiad Veracruzana, Xalapa, Ver., Mexico

## Editorial Board

Lorena Abadia-Patino, IIBCAUDO, Venezuela

Ishag Adam, Faculty of Medicine, University of Khartoum, Sudan, Sudan

Guillermo Daniel Alonso, INGEBI (UBA-CONICET), Buenos Aires, Argentina

Martin Antonio, Medical Research Council Laboratories, Fajara, Gambia

Mustafa Altindis, Sakarya University, School of Medicine, Dept of Clinical Virology and Microbiology, Sakarya, Turkey

George Farah Araj, American University of Beirut Medical Center, Lebanon

Omar Bagasra, Claflin University Orangeburg, United States

Jesus F. Bermejo-Martin, Unidad de Investigación en Infección e Inmunidad, Hospital Clínico Universitario de Valladolid, National Centre of Influenza, Valladolid, Spain

Norma Binsztein, Dept Bacteriology, National Institute of Infectious Diseases, Buenos Aires, Argentina

Stuart D Blacksell, Principal Scientist/Health & Safety team leader, BAppSc MPH PhD FFSc FASM RBP, MORU | 420/6 Rajvithi Rd, BKK, Thailand, 10400

Maria Braoudaki, First department of Pediatrics, University of Athens, Greece

Denis Karuhize Byarugaba, Makerere University, Kampala, Uganda

Adrian Canizalez-Roman, Faculty of Medicina and The Sinaloa State Public Health Laboratory, Mexico

Nora Cardona-Castro, Instituto Colombiano de Medicina Tropical - Universidad CES, Sabaneta, Antioquia, Colombia

Jean-Philippe François Chippaux, Institut de Recherche pour le Développement, France

John David Clemens, International Vaccine Institute, Korea, Republic Of

Ricardo Correa, ICGES, Panama

Tulsi Dass Chugh, BLK memorial hospital, New Delhi 110005, India

Nigel Cook, Food and Environment Research Institute, Sand Hutton, York, United Kingdom

Fazal Karim Dar, Arabian Gulf University, Bahrain

Tamer Ahmad Essawi, Birzeit University, Palestinian Territory, Occupied

Giovanni Fadda, Universita' Cattolica, Roma, Italy

Bernardino Fantini, University of Geneva, Geneva, Switzerland

Marcelo Ferreira, Department of Parasitology, Institute of Biomedical Sciences, Brazil

Márió Gajdács, Faculty of Dentistry, University of Szeged, Hungary

John David Klena, US CDC, United States

Christopher H Logue, Public Health England, United

Danilo Lo Fo Wong, World Health Organization, Denmark da spostare nell editorial board

Jawhar Gharbi, University of Monastir, Tunisia

Amy Gassama Sow, Pasteur Institute, Dakar, Senegal

Gerardo E. González-Rocha, Universidad de Concepcion, Concepcion, Chile

Humberto Guerra, Universidad Peruana Cayetano Heredia, Peru

Deniz Gur, Hacettepe University, İ.Doğramacı Children's Hospital, Clinical Microbiology lab, Ankara, Turkey

José Gutiérrez-Fernández, Microbiology Area. Hospital Virgen de las Nieves-University of Granada, Spain

Yadav Prasad Joshi, Department of Social and Preventative Medicine, Sungkyunkawn University, South Korea

Shahana Urooj Kazmi, Department of Microbiology, University of Karachi, Pakistan

Kewal Krishan, Department of Anthropology, Panjab University, Chandigarh, India

Kamal Kishore, Fiji School of Medicine, Suva, Fiji

An Van Le, Department of medical microbiology, Hue College of medicine and Pharmacy, Viet Nam

Vittorio Mazzarello, Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy

Grant McFadden, University of Florida, United States

Paola Molicotti, Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy

Ziad Nasr, Department of Clinical Pharmacy and Practice, College of Pharmacy, Qatar University, Qatar

Rogelio Navarrete Castro, Enfermedades Infecciosas, Hospital Ángeles Metropolitano. Centro de Atención y Capacitación en Enfermedades Infecciosas S.C. CCIN, México.

Rajesh Nayak, U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, United States

Behrouz Nikbin, Tehran University of Medical Sciences, Dept. of Immunology, Iran, Islam

Fulgence Nzabintwali, LNR, Kigali, Rwanda, Rwanda

Celso José Bruno Oliveira, Center for Agrarian Sciences - Federal University of Paraíba, Brazil, Brazil

Guadalupe Ortega-Pierres, Department of Genetics and Molecular Biology Centro de Investigación y Estudios Avanzados IPN, Mexico

Tibor Pal, Department of Medical Microbiology, FMHS, UAE University, Al Ain, United Arab Emirates

Bodh Raj Panhotra, Dept Medical Microbiology, SBS Postgraduate Inst Biomedical Sci. & Res, India

Violeta Trinidad Pardío, Universidad Veracruzana, Mexico

Christopher M Parry, University of Liverpool, United Kingdom

Gianfranco Pintus, Department of Biomedical Sciences, University of Sassari, Italy

Paola Rappelli, Department of Biomedical Sciences, University of Sassari, Italy

Davide Rizzo, University of Sassari, Italy

David Rodríguez-Lázaro, Instituto Tecnológico Agrario de Castilla y León , (ITACYL). Laboratorio de Biología Molecular, Valladolid, Spain

Vincent O. Rotimi, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait

Giuseppina Sanna, Department of Biomedical Science, Section of Microbiology and Virology, University of Cagliari, Cagliari, Italy

Renato L. Santos, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Shamala Devi Sekaran, University Malaya, Kuala Lumpur, Malaysia

Moustafa Ahmed El-Shenawy, National Research Center, Dokki-Cairo, Egypt

Seyed Davar Siadat, Pasteur Institute of Iran, Tehran, Iran, Islamic Republic Of

Roy D Sleator, Cork Institute of Technology, Ireland

Alicia Ponte Sucre, Universidad central de Venezuela, Venezuela

Ibrahim Taher, Medical Microbiology AL-Jouf University, Skaka KSA, Saudi Arabia

Luís Távora Tavira, Centre for Malaria & Tropical Diseases - IHMT, Lisboa, Portugal

Jaffar A. Al-Tawfiq, Saudi Aramco Medical Services organization, Saudi Arabia

Mohammed Timinouni, Institut Pasteur Maroc, Morocco

Thang Van Vo, Hue college of Medicine and Pharmacy, Hue, Viet Nam

Gianpaolo Vidili, Scienze Mediche Chirurgiche e Sperimentali, Università di Sassari, Sassari, Italy

Yoshio Yamaoka, Baylor College of Medicine, Houston, Texas, United States, Faculty of Medicine,  
Mansoura University, Children Hospital, Egypt

Jan C. Wilschut, University Medical Center Groningen, Netherlands

Raffaele Zarrilli, Department of Preventive Medical Sciences University of Naples, Italy

## **Technical Editor**

Nikki Ann Kelvin, JIDC

Maria Grazia Del Giudice, JIDC

Matthew Gavino Donadu, Università di Sassari, Sassari, Italy

## **Assistant to the Technical Editor and Linguistic Division**

Eva Molak, Canada

Claire White, United Kingdom

## **Scientific Editor**

Nadia Ahmod, Health Protection Agency, United Kingdom

Eve Boakes, United Kingdom

Antigoni Chaidaroglou, Greece

Marie Anne Chattaway, HPA, Colindale, United Kingdom

Daniela Chessa, Universita' di Sassari, Italy

Wafa Habbal, Damascus University, Syrian Arab Republic

Richard C Huard, Columbia Univ Med Ctr, NewYork Presbyterian Hosp, United States

Adnan Khan, Karachi University, Pakistan

Gemma C Langridge, Wellcome Trust Sanger Institute, United Kingdom

Alicia San José, Nurse, Spain

Helena MB Seth-Smith, Sanger Institute

Chengming Wang, Ross University School of Veterinary Medicine, Saint Kitts and Nevis

## **IT Department**

Marco Scano, Italy



## Original Article

**Polymerase chain reaction of human cytomegalovirus from liver and urine compared with serological test in cholestasis infants**

Alphania Rahniayu<sup>1,2</sup>, Gondo Mastutik<sup>1</sup>, Anny Setijo Rahaju<sup>1,2</sup>, Siti Eriaty Nur Ruslan<sup>3</sup>, Priangga Adi Wiratama<sup>2</sup>, Erna Sulistiyani<sup>4</sup>, Bagus Setyoboedi<sup>5,6</sup>

<sup>1</sup> Department of Anatomic Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

<sup>2</sup> Department of Anatomic Pathology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

<sup>3</sup> Institute of Tropical Diseases, Universitas Airlangga, Surabaya, Indonesia

<sup>4</sup> Department of Oral Medicine, Faculty Dentistry, Jember University, Jember, Indonesia

<sup>5</sup> Department of Child Health, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

<sup>6</sup> Department of Child Health, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

**Abstract**

**Introduction:** The most common infection in cholestatic infants is caused by human cytomegalovirus (HCMV). The aims were to detect the presentation of HCMV in cholestatic infants and to evaluate the concordance, sensitivity, and specificity between serology and polymerase chain reaction (PCR) of HCMV from liver biopsy and urine specimens.

**Methodology:** A descriptive observational study with a cross-sectional approach was conducted on 35 cholestatic infants with ethical approval. Specimens were liver biopsy, urine, and anti-HCMV serology. Liver and urine specimens were performed to nested PCR, followed by statistical analysis.

**Results:** PCR from the liver biopsy and urine specimen were positive in 74.3% and 85.7%, respectively. There was no concordance between IgM with the liver PCR, but there was a concordance between IgM with the urine PCR and between IgG with the liver and urine PCR. The sensitivity and specificity of IgM with the liver PCR were 46 % and 56%, respectively, with a diagnostic accuracy of 49%. While IgG sensitivity was 96% with a diagnostic accuracy of 80%. IgG sensitivity and IgM specificity compared with the urine PCR were 93% and 100%, respectively, with a diagnostic accuracy of more than 60%.

**Conclusions:** It demonstrates a high prevalence of HCMV DNA in urine and liver biopsy from cholestatic infants. HCMV PCR assay is more sensitive and specific than the anti-HCMV IgM, but IgG has high sensitivity and accuracy diagnostic. Therefore, serological examination is an option for diagnosing HCMV infection in cholestatic infants in developing countries with no PCR facilities.

**Key words:** Infant mortality; infectious disease; developing country; human cytomegalovirus.

*J Infect Dev Ctries* 2022; 16(10):1630-1636. doi:10.3855/jidc.16851

(Received 17 May 2022 – Accepted 26 July 2022)

Copyright © 2022 Rahniayu *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Introduction**

The infant mortality rate in developing countries is still high. One of the causes is cholestasis. The incidence of cholestasis in infants is associated with congenital abnormalities or viral infections. The most common cause of infection was Human cytomegalovirus (HCMV) infection [1]. Data showed that the seroprevalence of HCMV in women of childbearing age is approximately 40-80% in a developed country and 90-100% in developing countries [2]. Therefore, it causes the congenital transmission of the virus from mothers who are primary HCMV infected to the fetus [3,4]. This congenital infection of HCMV occurs in approximately 0.5-0.7% of live births [3,5,6]. Most infected newborns are

asymptomatic [3,5], but approximately 11% of live birth with congenital HCMV infection were symptomatic [3] such as jaundice (62%), petechiae (58%), hepatosplenomegaly (50%) [1], and up to 20% develop sensorineural hearing loss or other permanent neurologic sequelae [5] and lead to permanent disabilities [3]. Therefore, proper early diagnosis is very important in order to provide appropriate therapy and reduce the occurrence of permanent disability.

Currently in Indonesia, the most frequently used method for diagnosing HCMV infection is a serological examination of anti-HCMV immunoglobulin M (IgM) and immunoglobulin (IgG) from blood samples. The presentation of IgM antibody to HCMV is formed approximately 1-2 weeks after infections, the titer peaks

in 1-3 months, then begins to decrease, and remains detectable up to 4 months [4,5,7]. In addition, anti-HCMV IgG can be detected 2-3 weeks after the appearance of symptoms [4,5] and maternally anti-HCMV IgG from the mother can be detected up to 8 months [2]. However, the sensitivity of IgM detection is still low where IgM was found to be negative in more than 50% of symptomatic children, while in asymptomatic children it was 78% [8]. Therefore, serological examination of anti-CMV IgM and IgG in newborns still cannot fully indicate the presence of HCMV infection in infants.

Polymerase chain reaction (PCR) examination is a virological detection method that is useful in diagnosing viral diseases because of its ability to detect very small amounts of viral DNA. HCMV DNA from infants can be isolated from body tissues such as liver biopsy tissues and body fluids such as tears, salivary, and urine [9,10]. The most common gene target area is the immediate early (IE) gene. On 2-4 hours after infection, the IE gene begins to activate the replication process, and intact virions spread in all body fluids within 48-72 hours after infection [11,12]. Therefore, the presentation of HCMV DNA can be detected from body fluids on the second or third day after infection. The objective of this study was to detect the presentation of HCMV DNA in the liver tissues and urine specimens from infants with cholestasis by PCR and to evaluate the concordance of the IgM and IgG anti-HCMV with PCR of HCMV from liver tissues and urine, as well as the sensitivity and specificity of serological test compared to PCR.

## Methodology

### *Sample collection*

This study was a descriptive observational study with a cross-sectional approach. This study has received approval from the ethical commission with ethical clearance number 729/Panke.KKE/XII/2017. All parents or guardians of the subjects in this study have received an informed consent explanation and were willing to participate in this study.

The samples were 35 infants with cholestasis who were treated at the Pediatric Inpatient Installation, Department of Child Health, Dr. Soetomo General Academic Hospital Surabaya in the period December 2017 to December 2018. The operational definition of cholestasis in this study was infants with jaundice, where the conjugated bilirubin level is 20% of the total bilirubin level (if the total bilirubin is greater than (>) 5 milligrams per deciliter (mg/dL) or the direct bilirubin level is > 2 mg/dL (if the total bilirubin is less than (<)

5 mg/dL). Specimen taken from patients were liver biopsy, urine, and serological data. Inclusion criteria were infants with cholestasis and aged 1 to 6 months. Exclusion criteria were patients who had received antiviral therapy, HIV patients, miliary tuberculosis patients, malnourished patients, history of using immunosuppressive drugs such as corticosteroids and cytostatic, platelets < 80.000 mg/dL, prolonged hemostasis function, and ascites.

### *Serological data collection*

Serological examination, which includes anti-HCMV IgM and IgG levels was examined by the Enzyme Linked Fluorescent Assay (ELISA) method using a solid phase receptacle from VIDAS. The interpretation of IgM was that IgM index unit < 0.7 was negative, < 0.7 to 0.9 was equivocal, > 0.9 was positive. The interpretation of IgG was that IgG index unit < 4 was negative, > 4 to < 6 was equivocal, and > 6 was positive.

### *HCMV PCR from liver biopsy and urine specimens*

The liver biopsy and urine specimens were collected in a sterile collection tube and then taken to the Institute of Tropical Diseases, Airlangga University for identification of HCMV infection by nested PCR. Extraction was carried out using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) according to the protocol then followed by PCR using primer as reported previously [13,14].

The  $\beta$  globin gene PCR was performed using PCO3+ and PCO4+ primers and the PCR Mastermix (PROMEGA, Madison, USA) which product size were the 325 base pair (bp). The compositions were 10  $\mu$ L master mix (Promega), 1  $\mu$ L PCO3+ (in a concentration of 10 picomole), 1  $\mu$ L PCO4+ (in a concentration of 10 picomole), 5  $\mu$ L ddH<sub>2</sub>O, 3  $\mu$ L DNA template. The initial denaturation 5 minutes at 94 °C for 1 cycle, then 30 seconds of denaturation at 94 °C, 30 seconds of annealing at 55 °C, 45 seconds of elongation at 72 °C, for all were in 40 cycles, and then 7 minutes for final elongation at 72 °C.

The PCR of HCMV DNA was performed using the MIE4 and MIE5 primers which resulted in size 435 bp for the first round and the IE1 and IE2 primer for the second round which resulted in size 161 bp. The compositions were 10  $\mu$ L master mix (Promega), 1  $\mu$ L the forward primer, 1  $\mu$ L the reverse primer, 4  $\mu$ L ddH<sub>2</sub>O, and 4  $\mu$ L the DNA template. The PCR conditions were 5 minutes of initial denaturation at 94 °C, 30 seconds of denaturation at 94 °C, 30 seconds of annealing at 67 °C, and 45 seconds of elongation at 72

°C. All were carried out for 40 cycles, then 7 minutes for final elongation at 72 °C.

**Statistical Analysis**

The presentation of HCMV DNA in liver biopsy and urine specimens was shown in percentage. The concordance of anti-HCMV IgM and IgG with HCMV PCR from liver and urine specimens was analyzed by the Fisher’s Exact Test 2-sided and McNemar. The sensitivity and specificity were shown in percentage.

**Ethical permission**

The ethical was obtained from the Dr. Soetomo General Academic Hospital, Surabaya, number 729/Panke.KKE/XII/ 2017.

**Results**

There were 35 infants with cholestasis involved in this study, consisting of 20 males and 15 females aged between 1 to 6 months (mean ± SD = 2.771 ± 1.087). The levels of direct/conjugated bilirubin (D Bil) were 7.955 ± 4.674 (mean ± SD) and the total bilirubin (T Bil) was 10.369 ± 5.896 (mean ± SD) (Table 1).

All samples in this study showed positive results for PCR of the β globin gene, hence continued with detection of HCMV. The result of HCMV PCR from liver tissues and urine specimens were positive in 26/35

**Table 1.** Patient Characteristics.

| Characteristics                    |                |
|------------------------------------|----------------|
| Age (mean ± SD)                    | 2.771 ± 1.087  |
| Age (N (%))                        |                |
| 1-2 month                          | 18 (51.4)      |
| 3-4 month                          | 14 (40)        |
| 5-6 month                          | 3 (8.6)        |
| Sex (N (%))                        |                |
| Male                               | 20 (57.1)      |
| Female                             | 15 (42.9)      |
| <b>Bilirubin index</b> (mean ± SD) |                |
| Direct Bilirubin                   | 7.955 ± 4.674  |
| Total Bilirubin                    | 10.369 ± 5.896 |


SD: Standard Deviation; N: Number.

(74.3%) and in 30/35 (85.7%) infants, respectively. The product of HCMV PCR is shown in Figure 1.

Serological data showed that IgM positive were found in 16/35 (45.7%) infants and IgG positive were found in 31/35 (88.6%) infants. Acute infection (IgM+ and IgG+), past infection (IgM- and IgG+), and uninfected (IgM- and IgG-) were found in 16/35 (45.7%), 15/35 (42.9%), and 4/35 (11.4%) infants, respectively (Table 2).

There was no concordance between anti-HCMV IgM with HCMV PCR from liver biopsy ( $p > 0.05$ ;  $p = 0.929$ ), but there was concordance between anti-HCMV IgM with HCMV PCR from urine specimens ( $p < 0.05$ ,  $p = 0.027$ ) which kappa coefficient was 0.246 (fair: 0.21 – 0.4) (Table 3).

**Figure 1.** The β-globin gene PCR result size 110 base pair (bp) in lane 2, 3, 4, 5 (A) and the HCMV PCR result size 435 bp for first round in lane 2, 3, 4 and 161 bp for second round in lane 5, 6 (B). The line 1 is PCR marker.



**Table 2.** HCMV PCR and anti-HCMV serological from infants with cholestasis.

| Characteristics                 | N (%)     |
|---------------------------------|-----------|
| <b>HCMV PCR from Liver</b>      |           |
| Positive                        | 26 (74.3) |
| Negative                        | 9 (25.7)  |
| <b>HCMV PCR from Urine</b>      |           |
| Positive                        | 30 (85.7) |
| Negative                        | 5 (14.3)  |
| <b>Serological anti-HCMV</b>    |           |
| IgM Positive                    | 16 (45.7) |
| IgM Negative                    | 19 (54.3) |
| IgG Positive                    | 31 (88.6) |
| IgG Negative                    | 4 (11.4)  |
| IgM +, IgG + (acute infections) | 16 (45.7) |
| IgM -, IgG + (past infection)   | 15 (42.9) |
| IgM -, IgG - (uninfected)       | 4 (11.4)  |

HCMV: human cytomegalovirus; PCR: polymerase chain reaction; IgM: immunoglobulin M; IgG: immunoglobulin G.

**Table 3.** The concordance of anti-HCMV IgM with HCMV PCR from liver biopsy and urine specimens.

| The specimens of HCMV PCR | IgM        |            | Total     | Coefficient Kappa | p value |
|---------------------------|------------|------------|-----------|-------------------|---------|
|                           | Positive   | Negative   |           |                   |         |
| Liver - Positive          | 12 (46.2%) | 14 (53.8%) | 26 (100%) | 0.013             | 0.929   |
| Liver - Negative          | 4 (44.4%)  | 5 (55.6%)  | 9 (100%)  |                   |         |
| Urine - Positive          | 16 (53.3%) | 14 (46.7%) | 30 (100%) | 0.246             | 0.027   |
| Urine - Negative          | 0 (0%)     | 5 (100%)   | 5 (100%)  |                   |         |

HCMV: human cytomegalovirus; PCR: polymerase chain reaction; IgM: immunoglobulin M.

**Table 4.** The concordance of anti-HCMV IgG with HCMV PCR from liver biopsy and urine specimens.

| The specimens of HCMV PCR | IgG        |           | Total     | Coefficient Kappa | p value |
|---------------------------|------------|-----------|-----------|-------------------|---------|
|                           | Positive   | Negative  |           |                   |         |
| Liver - Positive          | 25 (96.2%) | 1 (3.8%)  | 26 (100%) | 0.360             | 0.017   |
| Liver - Negative          | 6 (66.7%)  | 3 (33.3%) | 9 (100%)  |                   |         |
| Urine - Positive          | 28 (93.3%) | 2 (6.7%)  | 30 (100%) | 0.364             | 0.030   |
| Urine - Negative          | 3 (60%)    | 2 (40%)   | 5 (100%)  |                   |         |

HCMV: human cytomegalovirus; PCR: polymerase chain reaction; IgG: immunoglobulin G.

There was concordance between anti-HCMV IgG with HCMV PCR from liver biopsy ( $p < 0.05$ ;  $p = 0.017$ ) and from urine specimens ( $p < 0.05$ ;  $p = 0.030$ ) with kappa coefficient were 0.360 for HCMV PCR from liver biopsy and 0.364 for HCMV PCR from urine specimens (fair: 0.21 – 0.4) (Table 4).

McNemar (exact sig 2-sided) test showed that there was a significant difference between HCMV PCR from liver biopsy and urine specimens with anti-HCMV IgM ( $p < 0.05$ , liver: 0.031, urine:  $< 0.001$ ), but there was no significant difference between HCMV PCR from liver biopsy and urine specimens with anti-HCMV IgG ( $p > 0.05$ , liver: 0.125, urine: 1.000) (Table 5).

The sensitivity and specificity of IgM anti-HCMV compared with HCMV PCR of liver biopsy specimens were 46.15% and 55.55%, respectively, with a diagnostic accuracy of 48.57%. While the sensitivity of anti-HCMV IgG is 96.15% with a diagnostic accuracy of 80%. In addition, the sensitivity of IgG and specificity of IgM compared to HCMV PCR of urine specimen showed 93.33% and 100%, respectively, with a diagnostic accuracy of more than 60% (Table 5).

## Discussion

Cholestasis is a decrease or obstruction of bile flow at any stage to the extrahepatic biliary tract and duodenum with the main symptoms of cholestasis are jaundice, acholic stools, and dark urine [15-17]. This condition is the most common cause of morbidity and mortality in infants and children. The accumulation of bile acids has an impact on hepatotoxicity. Therefore, it becomes the underlying cause of liver disorders [18]. The identity of prolonged neonatal jaundice more than 2 weeks of early life is an essential procedure for an early diagnosis of cholestasis diseases [10]. The inability to detect and monitor the progression of liver

damage will hinder the appropriate management of cholestatic disease.

The most common causes of cholestasis are biliary atresia,  $\alpha$ -1 antitrypsin deficiency, and infection, including HCMV infection [20]. HCMV can be transmitted horizontal or maternal from mother to fetus or infant [21]. In this study, the time of infection could not be determined whether during prenatal, natal or postnatal periods, due to the age of infants involved in this study was variable from 1 to 6 months, even though more than 50% of cholestasis occurred in 1 to 2 months infants. This requires further confirmation.

This study used specimens from liver biopsy and urine. It showed high prevalence of HCMV DNA in cholestatic infants. HCMV DNA detected in more than a half of patient that was 74.3% of liver tissue and 85.7% of urine. Another study in liver biopsy tissues in cholestasis infants showed that 48% [22], 34.3% [23], and 52% [24] patients were positive for HCMV DNA. In a Brazilian study on patients with extrahepatic cholestasis, of 33 liver biopsy samples examined by HCMV PCR, 27.3% were positive for HCMV DNA [23]. Research in Egypt involving 94 patients with biliary atresia and 91 patients with neonatal cholestasis due to other causes (non-biliary atresia), the frequency of HCMV DNA by PCR examination of liver biopsy in patients with biliary atresia was 5.3%, non-biliary atresia 23% [25]. In addition, PCR of urine samples was considered the optimal sample for the detection of HCMV infection in newborns. The PCR results showed that there were 79 of 80 (98.8%) positive urine samples [26].

The use of PCR as a diagnostic method in developing countries is not routinely carried out due to limited equipment and funds. Therefore, serological examination is still used as an alternative method for

**Table 5.** Sensitivity and Specificity of anti-HCMV serology compared with HCMV PCR from liver biopsy and urine specimens.

| Serology compared with HCMV PCR | Sensitivity | Specificity | PPV    | NPV    | DA     | Mc Nemar  |
|---------------------------------|-------------|-------------|--------|--------|--------|-----------|
| IgM compared with Liver         | 46.15%      | 55.55%      | 75.00% | 26.31% | 48.57% | 0.031     |
| IgG compared with Liver         | 96.15%      | 33.33%      | 71.42% | 75%    | 80%    | 0.125     |
| IgM compared with Urine         | 53.33%      | 100%        | 100%   | 26.31% | 60%    | $< 0.001$ |
| IgG compared with Urine         | 93.33%      | 40%         | 90.32% | 50%    | 85.71% | 1         |

HCMV: human cytomegalovirus; PCR: polymerase chain reaction; IgM: immunoglobulin M; IgG: immunoglobulin G; PPV: positive predictive value; NPV: negative predictive value; DA: diagnostic accuracy

diagnosing HCMV infection. Serological tests are very useful to determine infection condition, acute infection, or recent infection by examining the IgM or in past infections by examining the presence of HCMV IgG [11,15]. This study showed that there were 45.7% of cholestatic infants in acute infection and 42.9% in past infection. In addition, the data showed that anti-HCMV IgM was in 45.7% and IgG was 88.6% of cholestatic infants. Other studies showed that IgM positive for HCMV in neonatal cholestasis in Sweden was 32.2% and IgG positive was 90% [22] and in Brazil, 28.9% was positive for IgM, both in intra and extra hepatic cholestasis [1]. Neonatal cholestasis in Egypt, IgM HCMV was positive in 12.4% [25]. In addition, other studies in India showed that anti-HCMV IgM was positive in 42% of patients and anti-HCMV IgG was positive in 84% of patients in neonatal cholestasis [24]. The IgM in primary infection of neonatal, showed the IgM reaches the peak at the first of 1 to 3 months, and later the titer begins to decrease [7], but persistent anti-HCMV IgM in the low level usually can be detected in more than 3 months or up to a year [7]. On the other hand, the maternal IgG of HCMV in infants will disappear at 8 months [2].

This study showed that there was concordance between anti-HCMV IgM with HCMV PCR from urine specimens with fair strength of agreement (0.246). It showed all infants with IgM positive were positive PCR from urine specimens. Furthermore, there was no concordance between anti-HCMV IgM with HCMV PCR from liver biopsy, that 12/16 (46.2%) infants with positive anti-HCMV IgM were positive for HCMV PCR. There were 4 infants who showed IgM positive and HCMV PCR negative. This may be because IgM can persist for 6 to 9 months after primary infection [11]. Therefore, IgM serology results are still positive while viral DNA is negative. In addition, there were 5 out of 19 infants with IgM negative, but PCR from liver and urine specimens were positive. This is in accordance with other studies which suggested that the serological examination of HCMV turned out to be a less accurate marker of HCMV infection in liver tissue [24]. The accuracy of serology for detecting HCMV antibodies was low [23]. The positivity of anti-HCMV IgM or HCMV DNA does not indicate the cause of cholestasis, but it implies that the virus may have influenced the severity of the original pathology [25].

This study showed the concordance of anti-HCMV IgG with HCMV PCR from liver and urine specimens with fair strength of agreement. Among 31 cholestatic infants with positive anti-HCMV IgG, there were 25 (96.2%) infants were positive for HCMV PCR from

liver tissue specimens and 28 (93.3%) infants were positive for HCMV PCR from urine specimens. The liver and urine specimens of some infants showed HCMV PCR negative and IgG was positive. The presentation of IgG anti-CMV indicates a past infection, where anti-CMV IgG antibodies were produced for 2 weeks post-infection and persisted for years [11]. Data showed the infants were 3 to 5 months age. This suggested that the virus may have infected in the past. In addition, there were 3 of liver and 2 urine specimens with IgM, IgG, and HCMV DNA were negative. This might indicate that the infants were not infected with HCMV, while the cholestasis was caused by others etiologies [24].

In this study, HCMV PCR from urine specimen had sensitivity higher than specimen from liver, that was 92.31% with the accuracy diagnostic was 77%. HCMV PCR is a highly sensitive method for detecting HCMV in variable clinical samples [11]. In addition, urine specimens are easy to collect, non-invasive, and large amounts of viral shedding are found in body fluids including urine [11]. It is different from a liver biopsy. It is difficult, invasive, and painful, require the proper skills and radiological equipment. Therefore, urine sample was more feasible to use as specimen for PCR in diagnosing HCMV infection of cholestatic infants.

In this study, sensitivity and specificity of IgM anti-HCMV compared with HCMV PCR of liver biopsy specimens were 46.15% and 55.55%, respectively, with a diagnostic accuracy of 48.57%. In addition, anti-HCMV IgG still had a high sensitivity of 96.15% in the liver and 93.33 % in urine specimens. This is in accordance with previous studies which stated that the HCMV PCR test was more sensitive and specific than the anti-HCMV serological test [24]. Sensitivity and specificity of anti-HCMV IgM compared with HCMV PCR from liver samples were 69% and 61%, respectively [24]. The sensitivity and specificity of PCR is higher than that of antigenemia, the sensitivity can reach 100%, the specificity is 72-90%, the positive predictive value is 69-90%, and the negative predictive value is 100% [27,28]. In addition, these results indicates that serological examination, when compared with HCMV PCR from urine specimens, shows high diagnostic accuracy that more than 60%. Therefore, in remote areas or area that do not have PCR equipment, the serological examination can still be an option for detecting HCMV infection in cholestatic infants. However, the anti-HCMV serological examination cannot replace PCR [29], so in health centers that have an access to perform PCR, PCR remains a necessity in

diagnosing cholestatic infants because it has higher sensitivity and specificity.

## Conclusions

This study demonstrated a high prevalence of HCMV DNA in the urine and liver biopsy specimens of cholestatic infants. HCMV PCR in urine had higher sensitivity than in the liver with a diagnostic accuracy of about 77%. Considering this and the patient is an infant, urine is the more widely available specimen for use in the diagnosis of CMV infection in cholestatic infants.

This study found no concordance between IgM with the PCR liver, but there was concordance between IgM with the PCR urine, and between IgG with the PCR liver and urine. In addition, HCMV PCR test was more sensitive and specific than the anti-HCMV serological test which IgM compared with the PCR liver has sensitivity and specificity of about 50%, and compared with the urine PCR has a sensitivity of 53% and specificity of 100%, with the diagnostic accuracy of 60%. Furthermore, IgG compared with the PCR urine has a high sensitivity of 95% with a high accuracy diagnostic of more than 80%, but has a low specificity. Considering the vast territory of Indonesia which consists of thousands of islands, there are still many health centers that lack equipment to perform PCR. Therefore, serological examination is an option for diagnosing HCMV infection in infants with cholestasis. This can also be applied in other developing countries that have not yet reached PCR testing services.

## Acknowledgements

This study was supported by Faculty of Medicine, the Universitas Airlangga in research contract number 259/UN3.1.1/PT/2021. We thank to all patients who are willing to participate, Government of the Republic of Indonesia, and the Universitas Airlangga.

## Funding

This study was supported by Faculty of Medicine, the Universitas Airlangga in research contract number 259/UN3.1.1/PT/2021.

## Authors' Contributions

All of the authors contributed to reading and approved the final manuscript. Alphania Rahniayu: main idea, writing, and editing manuscript, histopathological diagnoses. Gondo Mastutik: main idea, laboratory examinations, writing, and editing manuscript, reviewing. Anny Setijo Rahaju: reviewing and histopathological diagnoses. Siti Eriaty Nur Ruslan: laboratory examinations. Priangga Adi Wiratama:

statistical analysis. Erna Sulistiyani: reviewing manuscript. Bagus Setyoedi: collecting patients.

## References

- Oliveira NL, Kanawaty FR, Costa SC, Hessel G (2002) Infection by cytomegalovirus in patients with neonatal cholestasis. *Arq Gastroenterol* 39: 132-136.
- Chen J, Hu L, Wu M, Zhong T, Zhou YH, Hu Y (2012) Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children. *Virology* 9: 304.
- Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. *Rev Med Virol* 17: 253-276.
- Revello MG, Gerna G (2002) Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. *Clin Microbiol Rev* 15: 680-715.
- Gantt S, Bitnun A, Renaud C, Kakkar F, Vaudry W (2017) Diagnosis and management of infants with congenital cytomegalovirus infection. *Paediatr Child Health* 22: 72-74.
- Marsico C, Kimberlin DW (2017) Congenital cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment. *Ital J Pediatr* 43: 38.
- Gunkel J, van der Knoop BJ, Nijman J, de Vries LS, Manten GTR, Nikkels PGJ, Murk JL, de Vries JIP, Wolfs TFW (2017) Congenital cytomegalovirus infection in the absence of maternal cytomegalovirus-IgM antibodies. *Fetal Diagn Ther* 42: 144-149.
- Bilavsky E, Watad S, Levy I, Linder N, Pardo J, Ben-Zvi H, Attias J, Amir J (2017) Positive IgM in congenital CMV infection. *Clin Pediatr (Phila)* 56: 371-375.
- Soetens O, Fellous CV, Foulun I (2008) Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections. *J Clin Microbiol* 46: 943-946.
- Goegebuert T, Van Meensel B, Beuselinck K, Cossey V, Van Ranst M, Hanssens M, Lagrou K (2008) Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. *J Clin Microbiol* 47: 660-665.
- Ross SA, Novak Z, Pati S, Boppana SB (2011) Diagnosis of cytomegalovirus infections. *Infect Disord Drug Targets* 11: 466-474.
- Crough T, Khanna R (2009) Immunobiology of human cytomegalovirus: from bench to bedside. *Clin Microbiol Rev* 22: 76-98.
- Mastutik G, Kurniasari N, Rahniayu A, Rahaju AS, Ruslan SEN, Ilmiah K, Setyoedi B, Sulistyani E (2022) Detection of cytomegalovirus in urine specimen of cholestasis infants by polymerase chain reaction. *Res J Phar Tech* 15: 2151-2157.
- Situmorang L, Setyoedi B, Arief S, Mastutik G (2019) Infection of cytomegalovirus (CMV) in cholestasis infant with biliary atresia. *Indones J Clin Pathol Med Lab* 26: 175-181.
- Davis AR, Rosenthal P, Escobar GJ, Newman TB (2011) Interpreting conjugated bilirubin levels in newborns. *J Pediatr* 158: 562-565.
- Suchy FJ (2004) Neonatal cholestasis. *Pediatr Rev* 25: 388-396.
- Rashed YK, Saber MA, Tawfik M, Mourad WS (2013) Histopathological features and accuracy for diagnosing biliary atresia by prelaparotomy liver biopsy in Egypt. *Egypt Pediatr Assoc Gaz* 61: 42-45.

18. Pereira TN, Walsh MJ, Lewindon PJ, Ramm GA (2010) Pediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. *World J Gastrointest Pathophysiol* 1: 69-84.
19. Götze T, Blessing H, Grillhösl C, Gerner P, Hoerning A (2015) Neonatal cholestasis - differential diagnoses, current diagnostic procedures, and treatment. *Front Pediatr* 3: 43.
20. Fischler B, Lamireau T (2014) Cholestasis in the newborn and infant. *Clin Res Hepatol Gastroenterol* 38: 263-267.
21. Liu P, Guo L, Huang L, Zhao D, Zhen R, Hu X, Yuan X (2015) Analysis of factors affecting the prognosis of neonatal cholestasis. *Int J Clin Exp Med* 8: 8005-8009.
22. Fischler B, Ehrnst A, Forsgren M, Orvell C, Nemeth A (1998) The viral association of neonatal cholestasis in Sweden: A possible link between cytomegalovirus infection and extrahepatic biliary atresia. *J Pediatr Gastroenterol Nutr* 27: 57-64.
23. De Tommaso AM, Andrade PD, Costa SC, Escanhoela CA, Hessel G (2005) High frequency of human cytomegalovirus DNA in the liver of infants with extrahepatic neonatal cholestasis. *BMC Infect Dis* 5: 108.
24. Goel A, Chaudhari S, Sutar J, Bhonde G, Bhatnagar S, Patel V, Bhor V, Shah I (2018) Detection of cytomegalovirus in liver tissue by polymerase chain reaction in infants with neonatal cholestasis. *Pediatr Infect Dis J* 37: 632-636.
25. Sira MM, Sira AH, Elhenawy IA, Khalil FO (2016) Prevalence of serological markers of TORCH infections in biliary atresia and other neonatal cholestatic disorders. *Open J Pediatr Child Heal* 2: 13-17.
26. Ross SA, Ahmed A, Palmer AL, Michaels MG, Sánchez PJ, Bernstein DI, Tolan RW Jr, Novak Z, Chowdhury N, Fowler KB, Boppana SB, National Institute on Deafness and Other Communication Disorders CHIMES Study (2014) Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens. *J Infect Dis* 210: 1415-1418.
27. Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, Sánchez PJ, Bernstein DI, Tolan RW Jr, Novak Z, Chowdhury N, Britt WJ, Fowler KB (2011) Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. *N Engl J Med* 364: 2111-2118
28. Bhatia P, Narang A, Minz RW (2010) Neonatal cytomegalovirus infection: diagnostic modalities available for early disease detection. *Indian J Pediatr* 77: 77-79.
29. Setyoboedi B, Widayanti R, Arief S, Puspitasari D, Prihaningtyas RA (2021) The agreement of cytomegalovirus (CMV) serology examination and CMV polymerase chain reaction of liver tissue in infants with cholestasis. *Sri Lanka J Child Heal* 50: 43-48.

### Corresponding author

Gondo Mastutik, PhD  
Associate Professor  
Department of Anatomic Pathology  
Faculty of Medicine, Universitas Airlangga  
St. Prof. Dr. Moestopo No 47, Surabaya, 60131, Indonesia.  
Tel: +62-31-5020251  
E-mail: gondomastutik@fk.unair.ac.id

**Conflict of interests:** No conflict of interests is declared.